









Markets
/
Stocks
/
nasdaq-pre
/

Prenetics Global Ltd

PRE

12.000USD

+1.160+10.70%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

154.73MMarket Cap

LossP/E TTM



Prenetics Global Ltd

12.000

+1.160+10.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

113 / 506

Overall Ranking

216 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

26.000

Target Price

+139.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 132.61% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 30.62M.

Undervalued

The company’s latest PE is -3.15, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.73M shares, decreasing 25.38% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.14.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.29, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 17.31M, representing a year-over-year increase of 169.93%, while its net profit experienced a year-over-year increase of 21.26%.

Score

Industry at a Glance

Previous score

6.29

Change



Financials

5.56

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.27

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.63

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.91

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.85, which is -75.27% below the recent high of -0.70 and 48.78% above the recent low of -1.46.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Prenetics Global Ltd is 26.00, with a high of 26.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

26.000

Target Price

+139.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Prenetics Global Ltd

PRE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 12.17 and the support level at 8.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.32

Change

0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.632

Buy

RSI(14)

73.783

Buy

STOCH(KDJ)(9,3,3)

92.858

Overbought

ATR(14)

1.083

Low Volatility

CCI(14)

153.982

Buy

Williams %R

0.238

Overbought

TRIX(12,20)

1.330

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.566

Buy

MA10

10.053

Buy

MA20

8.856

Buy

MA50

8.295

Buy

MA100

7.934

Buy

MA200

6.439

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 32.59%, representing a quarter-over-quarter decrease of 7.51%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dennis (Lo Yuk Ming)

962.96K

Genetel Bioventures Ltd

613.79K

Lawrence (Tzang Chi Hung)

537.10K

Eastspring Investments (Singapore) Limited

427.96K

Aspex Management (HK) Limited

346.15K

Nomura Securities Co., Ltd.

333.53K

+3.27%

Chun (Lo Hoi)

162.62K

Morgan Stanley Smith Barney LLC

2.12K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.69, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.